MDxHealth Completes Bio Techne ExoDx Acquisition to Bolster Precision Diagnostics

MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of Bio-Techne Corporation’s ExoDx business, including the ExoDx Prostate test. This $15 million transaction is part of the company’s plan to strengthen its precision diagnostics portfolio.

Earlier on August 5, 2025, MDxHealth SA (NASDAQ:MDXH) signed a definitive agreement for the takeover with payment structured over the next few years. Under the terms, $5 million in stock will be paid at closing, while $2.5 million will be paid annually in the course of four years, half in cash and half in either cash or stock, at the company’s discretion.

Overall, MDxHealth SA (NASDAQ:MDXH) offers a diverse range of precision diagnostics, targeting all stages of prostate cancer and advanced UTI detection, a market worth $4.9 billion in itself. Despite potential competition from big names, the company’s “sticky adoption” is an incredibly bullish hint.

MDxHealth SA (NASDAQ:MDXH), headquartered in Herstal, Belgium, is a commercial-stage precision diagnostics company that offers Select mdx, Confirm mdx, and Resolve mdx. Incorporated in 2003, the company is committed to improving patient care and healthcare economics.

While we acknowledge the potential of MDXH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MDXH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.